Avadel Pharmaceuticals (AVDL) Liabilities and Shareholders Equity (2016 - 2022)
Historic Liabilities and Shareholders Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $145.8 million.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity fell 4480.72% to $145.8 million in Q3 2022 from the same period last year, while for Dec 2022 it was $524.8 million, marking a year-over-year decrease of 5171.32%. This contributed to the annual value of $247.3 million for FY2021, which is 2065.61% down from last year.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity amounted to $145.8 million in Q3 2022, which was down 4480.72% from $157.9 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $351.9 million during Q1 2018, and its lowest value of $145.8 million during Q3 2022.
- For the 5-year period, Avadel Pharmaceuticals' Liabilities and Shareholders Equity averaged around $239.6 million, with its median value being $247.3 million (2021).
- In the last 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity crashed by 5065.61% in 2019 and then skyrocketed by 11017.33% in 2020.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $190.3 million in 2018, then dropped by 20.42% to $151.4 million in 2019, then skyrocketed by 105.79% to $311.6 million in 2020, then fell by 20.66% to $247.3 million in 2021, then plummeted by 41.05% to $145.8 million in 2022.
- Its Liabilities and Shareholders Equity was $145.8 million in Q3 2022, compared to $157.9 million in Q2 2022 and $221.1 million in Q1 2022.